{
  "guideline": {
    "id": "PA166104997",
    "name": "Annotation of CPIC Guideline for abacavir and HLA-B",
    "source": "CPIC",
    "version": 48,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104997",
    "relatedChemicals": [
      {
        "id": "PA448004",
        "name": "abacavir",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166296758",
      "name": "Recommendation PA166296758",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA448004",
          "name": "abacavir",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059560,
        "html": "<p>Use abacavir per standard dosing guidelines</p>\n"
      },
      "implications": [
        "HLA-B: Low or reduced risk of abacavir hypersensitivity"
      ],
      "lookupKey": {
        "HLA-B": "*57:01 negative"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166296759",
      "name": "Recommendation PA166296759",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA448004",
          "name": "abacavir",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059561,
        "html": "<p>Abacavir is not recommended</p>\n"
      },
      "implications": [
        "HLA-B: Significantly increased risk of abacavir hypersensitivity"
      ],
      "lookupKey": {
        "HLA-B": "*57:01 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "24561393",
      "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.",
      "authors": [
        "Martin M A",
        "Hoffman J M",
        "Freimuth R R",
        "Klein T E",
        "Dong B J",
        "Pirmohamed M",
        "Hicks J K",
        "Wilkinson M R",
        "Haas D W",
        "Kroetz D L",
        "Clinical Pharmacogenetics Implementation Consortium"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2014,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994233"
    },
    {
      "pmid": "22378157",
      "title": "Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.",
      "authors": [
        "Martin M A",
        "Klein T E",
        "Dong B J",
        "Pirmohamed M",
        "Haas D W",
        "Kroetz D L",
        "Clinical Pharmacogenetics Implementation Consortium"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2012,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374459"
    }
  ],
  "version": "2024-02-29-20-19"
}